Nanobiotix SA
5NR
Company Profile
Business description
Nanobiotix SA is a clinical-stage biotechnology company that has one operating segment, which focuses on developing product candidates that use its proprietary nanotechnology to transform cancer treatment by increasing the efficacy of radiotherapy. The company develops NanoXray products to help patients receiving radiotherapy by magnifying the effect of radiotherapy within tumor cells without increasing the dose to surrounding healthy tissues. Its product candidate is NBTXR3, a preclinical research program for cancer immunotherapies.
Contact
60 Rue de Wattignies
Paris75012
FRAT: +33 140260470
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
103
Stocks News & Analysis
stocks
Will undervalued ASX share show progress in results?
Investors will get to see if the new strategy and capital management framework are working.
stocks
10 best US dividend aristocrats to buy now for 2026
These undervalued stocks with economic moats have increased their dividends for 25 consecutive years or more.
stocks
What to expect from the January Fed meeting
Central bankers are likely to hold interest rates steady, but Wall Street is focused on life after Powell.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,299.80 | 1.50 | -0.02% |
| CAC 40 | 8,166.02 | 34.87 | 0.43% |
| DAX 40 | 24,953.34 | 20.26 | 0.08% |
| Dow JONES (US) | 49,055.99 | 356.41 | -0.72% |
| FTSE 100 | 10,222.41 | 73.56 | 0.72% |
| HKSE | 27,126.95 | 361.43 | 1.35% |
| NASDAQ | 23,700.33 | 98.98 | 0.42% |
| Nikkei 225 | 53,333.54 | 448.29 | 0.85% |
| NZX 50 Index | 13,493.71 | 17.17 | -0.13% |
| S&P 500 | 6,962.46 | 12.23 | 0.18% |
| S&P/ASX 200 | 8,975.10 | 0.80 | 0.01% |
| SSE Composite Index | 4,139.90 | 7.30 | 0.18% |